The study is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of two dose regimens of certolizumab pegol (CZP) in subjects with active axial spondyloarthritis (axial SpA).
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01087762?cond=%22Arthritis%22&lup_s=07/28/2011&lup_d=30
